Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Erpingham House is the UK’s largest vegan restaurant whose aim is to make plant-based dining into the mainstream and provide delicious, healthy food and drinks to people. The company has earned nationwide recognition and, it has been listed in The Times top 20 vegetarian restaurants. It has also been featured in The Guardian and on channel 4’s “what Britain bought.” EH has served over 12,000 customers in its first year and, it has risen to over 20,000 followers on Instagram. The funds will be used to expand the brand & open a second site in Brighton.
days to go:
Expired
investment:
£192,280
Pomodoro e Basilico are a popular vegan artisan food stall with a loyal following and have been featured by major news outlets and celebrity chefs. They are looking to raise funds to launch London's first Italian, Vegan Deli-Bistro to fill the gap in the market for great, Italian inspired, vegan delis.
days to go:
Expired
investment:
Withheld
Harvey’s British Eatery is a 35 to 40 cover eatery focused on re-establishing the heritage of British cooking. Harvey’s recipes draw on the best in the British Isles, using seasonal ingredients. The investment will be used to take their eatery to a permanent site in London.
(SEIS partial)
days to go:
Expired
investment:
£193,550
10Cast forensic forecasting is a cloud and mobile AI application that integrates with legacy CRM systems to improve B2B forecasting.
days to go:
Expired
investment:
£90,056
Appital is an emerging financial market platform that will use digital profiling, unique algorithms and notifications to connect institutional demand and supply. With Appital, corporate and institutional companies within the equity capital markets space will have the opportunity to exchange illiquid equity without an investment bank or broker. Appital will also remove the dependence on email and phone, thereby ensuring efficiency and accessibility. The company is raising fund to built the Appital software, achieve FCA regulation, generate marketing material and gain contracts with partner settlement and KYC providers. Furthermore, the company will enhance the functionality of the software by leveraging its network to other products such as primary debt and primary equity deal flow.
days to go:
Expired
investment:
£349,060
The UK's first authentic iced milk tea / brewed chai, combining the speciality of flavoured teas with the status of milk tea. Tuk Tuk Chai launched in 2017 with products available at 110 Sainsbury’s stores and Harvey Nichols. The firm has won multiple awards including 'Most Innovative Product' at the Lunch! 2017 trade show and were finalists for 2017 Virgin Foodpreneur. In 2018, Peter Jones of Dragon's Den made an investment offer towards the company.
days to go:
Expired
investment:
£275,920
